Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.
Copper-64 (T(1/2) = 12.7 hours; beta(+), 0.653 MeV [17.8 %]; beta(-), 0.579 MeV [38.4 %]) has decay characteristics that allow for positron emission tomography (PET) imaging and targeted radiotherapy of cancer. The well-established coordination chemistry of copper allows for its reaction with a wide variety of chelator systems that can potentially be linked to peptides and other biologically relevant small molecules, antibodies, proteins, and nanoparticles. The 12.7-hours half-life of 64Cu provides the flexibility to image both smaller molecules and larger, slower clearing proteins and nanoparticles. In a practical sense, the radionuclide or the 64Cu-radiopharmaceuticals can be easily shipped for PET imaging studies at sites remote to the production facility. Due to the versatility of 64Cu, there has been an abundance of novel research in this area over the past 20 years, primarily in the area of PET imaging, but also for the targeted radiotherapy of cancer. The biologic activity of the hypoxia imaging agent, 60/64Cu-ATSM, has been described in great detail in animal models and in clinical PET studies. An investigational new drug application for 64Cu-ATSM was recently approved by the U.S. Food and Drug Administration (FDA) in the United States, paving the way for a multicenter trial to validate the utility of this agent, with the hopeful result being FDA approval for routine clinical use. This article discusses state-of-the-art cancer imaging with 64Cu radiopharmaceuticals, including 64Cu-ATSM for imaging hypoxia, 64Cu-labeled peptides for tumor-receptor targeting, (64)Cu-labeled monoclonal antibodies for targeting tumor antigens, and 64Cu-labeled nanoparticles for cancer targeting. The emphasis of this article will be on the new scientific discoveries involving (64)Cu radiopharmaceuticals, as well as the translation of these into human studies.
Anderson
Carolyn J
CJ
Mallinckrodt Institute of Radiology, Washington University School of Medicine, Campus Box 8225, St. Louis, MO 63110, USA. andersoncj@mir.wustl.edu
Ferdani
Riccardo
R
D000818:Animals; D003301:Copper Radioisotopes / Q000737:chemistry; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods; D019275:Radiopharmaceuticals / Q000737:chemistry
D003301:Copper Radioisotopes; D019275:Radiopharmaceuticals
Cancer Res. 1996 Oct 1;56(19):4509-15
8813149
Biomacromolecules. 2008 Jul;9(7):1997-2006
18510359
Ann Biomed Eng. 2006 Jan;34(1):15-22
16528617
Bioorg Med Chem. 2009 Jan 15;17(2):548-52
19101152
Cancer Res. 1999 Dec 1;59(23):5863-70
10606224
Biomacromolecules. 2007 Oct;8(10):3126-34
17880180
Chemistry. 2008;14(19):5890-907
18494010
Neoplasia. 2005 Mar;7(3):271-9
15799827
Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):850-8
17262214
Cancer Treat Rev. 2004 Feb;30(1):1-17
14766123
Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):844-50
12692685
Dalton Trans. 2007 Jun 7;(21):2150-62
17514336
J Nucl Med. 2008 Feb;49(2):201-5
18199612
Q J Nucl Med Mol Imaging. 2008 Sep;52(3):267-77
18475250
Biomacromolecules. 2005 Sep-Oct;6(5):2541-54
16153091
Nat Protoc. 2006;1(6):3062-8
17406569
Eur J Nucl Med. 1997 Apr;24(4):368-71
9096086
J Nucl Med. 2005 Oct;46(10):1707-18
16204722
J Nucl Med. 2008 Nov;49(11):1819-27
18927338
Nucl Med Biol. 2008 Aug;35(6):713-20
18678357
Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1206-11
11158618
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41
17056720
J Nucl Med. 2007 Feb;48(2):311-8
17268030
Bioconjug Chem. 2004 Jan-Feb;15(1):41-9
14733582
J Nucl Med. 1995 Oct;36(10):1818-24
7562049
Life Sci. 1982 Sep 13;31(11):1133-40
6128648
J Nucl Med. 1995 Dec;36(12):2315-25
8523125
Ann Nucl Med. 2000 Oct;14(5):323-8
11108159
J Nucl Med. 1992 May;33(5):652-8
1349039
J Am Chem Soc. 2006 Aug 30;128(34):11199-205
16925438
Appl Radiat Isot. 2007 Oct;65(10):1115-20
17669663
Cancer Res. 1998 Feb 1;58(3):437-41
9458086
Br J Cancer. 2004 Feb 9;90(3):561-5
14760364
J Nucl Med. 2004 Oct;45(10):1776-83
15471848
Nucl Med Commun. 1998 Mar;19(3):283-8
9625504
Clin Cancer Res. 1997 Dec;3(12 Pt 2):2703-7
10068277
Nucl Med Biol. 2003 Jul;30(5):535-9
12831992
J Nucl Med. 2008 Jul;49(7):1177-82
18552145
J Nucl Med. 2007 Jul;48(7):1162-71
17574975
Bioconjug Chem. 2009 Apr;20(4):750-9
19320477
Chemistry. 2003 Jan 3;9(1):233-48
12506380
Nat Nanotechnol. 2007 Jan;2(1):47-52
18654207
Bioconjug Chem. 2000 Jul-Aug;11(4):527-32
10898574
Cancer Res. 2002 Nov 1;62(21):6146-51
12414640
Technol Cancer Res Treat. 2004 Feb;3(1):33-40
14750891
Bioconjug Chem. 2003 Mar-Apr;14(2):388-94
12643749
Mol Imaging Biol. 2004 Sep-Oct;6(5):350-9
15380745
Int J Radiat Biol. 2006 Oct;82(10):699-757
17118889
Biomacromolecules. 2008 Apr;9(4):1329-39
18338840
Nucl Med Biol. 1999 May;26(4):351-8
10382836
J Med Chem. 2001 Aug 2;44(16):2636-60
11472217
Int J Cancer. 2000 Aug 20;90(4):186-98
10993959
J Nucl Med. 1997 Jul;38(7):1155-60
9225812
Nat Rev Cancer. 2002 Feb;2(2):91-100
12635172
Exp Neurol. 2005 Dec;196(2):381-9
16197944
Int J Biochem Cell Biol. 1997 May;29(5):721-5
9251239
Neurosurgery. 2001 Aug;49(2):380-9; discussion 390
11504114
ACS Nano. 2008 May;2(5):889-96
19206485
J Nucl Med. 2008 Aug;49(8):1371-9
18632815
J Nucl Med. 2007 Nov;48(11):1862-70
17942800
Clin Cancer Res. 2004 Dec 15;10(24):8674-82
15623652
Cancer Biother Radiopharm. 2008 Apr;23(2):158-71
18454685
Cancer Biother Radiopharm. 2001 Dec;16(6):483-94
11789025
Science. 2002 Apr 5;296(5565):151-5
11884718
Technol Cancer Res Treat. 2008 Apr;7(2):149-54
18345704
Cancer Res. 2009 Mar 15;69(6):2435-42
19276378
Nucl Med Biol. 2009 Apr;36(3):277-85
19324273
Q J Nucl Med Mol Imaging. 2008 Jun;52(2):101-6
18043544
Curr Opin Biotechnol. 2007 Feb;18(1):26-30
17254762
Nanomedicine (Lond). 2007 Jun;2(3):287-306
17716175
J Med Chem. 1999 Apr 22;42(8):1341-7
10212119
J Nucl Med. 1998 Nov;39(11):1944-51
9829587
Inorg Chem. 1999 Oct 4;38(20):4435-4446
11671154
Macromolecules. 2007;40(9):2971-2973
18779874
Nucl Med Biol. 1997 Jan;24(1):35-43
9080473
Am J Clin Nutr. 1996 May;63(5):797S-811S
8615367
Cancer Res. 1993 Sep 15;53(18):4322-8
8364927
Nucl Med Biol. 1999 Jan;26(1):117-21
10096511
Cell. 1992 Apr 3;69(1):11-25
1555235
FASEB J. 2005 Dec;19(14):2008-10
16204353
Basic Res Cardiol. 2008 Mar;103(2):122-30
18324368
Nucl Med Biol. 1999 Apr;26(3):267-73
10363797
Cancer Res. 1990 Oct 15;50(20):6757-64
2208139
Technol Cancer Res Treat. 2008 Feb;7(1):1-13
18198919
J Clin Invest. 1995 Oct;96(4):1815-22
7560073
J Med Chem. 2005 Apr 21;48(8):2985-92
15828837
J Biol Inorg Chem. 2003 Jan;8(1-2):217-25
12459917
Curr Pharm Biotechnol. 2004 Dec;5(6):495-507
15579039
J Bone Miner Metab. 2007;25(6):337-44
17968485
Q J Nucl Med Mol Imaging. 2008 Jun;52(2):185-92
18043536
J Med Chem. 2002 Jan 17;45(2):469-77
11784151
Cancer Metastasis Rev. 2008 Dec;27(4):631-44
18523730
J Nucl Med. 1999 Jan;40(1):177-83
9935074
Bioconjug Chem. 2002 Jul-Aug;13(4):721-8
12121126
Acta Crystallogr C. 2000 Jan;56 (Pt 1):37-9
10710660
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5844-9
18378895
J Biol Inorg Chem. 2002 Mar;7(3):249-59
11935349
Clin Physiol Biochem. 1986;4(1):11-9
3006968
J Nucl Med. 2001 Feb;42(2):213-21
11216519
Ultrasound Med Biol. 2007 Jun;33(6):950-8
17434667
Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):764-70
15785955
Drug Discov Today. 2005 Jan 1;10(1):35-43
15676297
Anal Biochem. 1985 Jul;148(1):249-53
4037304
J Med Chem. 2004 Mar 11;47(6):1465-74
14998334
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8
12654432